The medical use of an anti-c Met antibody-cytotoxic drug conjugate is described. In particular, an anti-c-Met antibody, an antigen-binding fragment thereof, a chimeric antibody and a humanized antibody containing the anti-c-Met antibody CDRs, and an antibody-cytotoxic drug conjugate thereof or a pharmaceutically acceptable salt or solvate thereof are described. Also described are the use of a pharmaceutical composition containing the humanized anti-c-Met antibody, the antigen-binding fragment thereof, the antibody-cytotoxic drug conjugate thereof, or the pharmaceutically acceptable salt or solvate thereof as an anti-hepatoma drug.